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Abstract
Malaria in sub-Saharan Africa has historically been almost exclusively attributed to Plasmo-
dium falciparum (Pf). Current diagnostic and surveillance systems in much of sub-Saharan
Africa are not designed to identify or report non-Pf human malaria infections accurately,
resulting in a dearth of routine epidemiological data about their significance. The high preva-
lence of Duffy negativity provided a rationale for excluding the possibility of Plasmodium vivax
(Pv) transmission. However, review of varied evidence sources including traveller infections,
community prevalence surveys, local clinical case reports, entomological and serological
studies contradicts this viewpoint. Here, these data reports are weighted in a unified frame-
work to reflect the strength of evidence of indigenous Pv transmission in terms of diagnostic
specificity, size of individual reports and corroboration between evidence sources. Direct
evidence was reported from 21 of the 47malaria-endemic countries studied, while 42 coun-
tries were attributed with infections of visiting travellers. Overall, moderate to conclusive evi-
dence of transmission was available from 18 countries, distributed across all parts of the
continent. Approximately 86.6 million Duffy positive hosts were at risk of infection in Africa in
2015. Analysis of the mechanisms sustaining Pv transmission across this continent of low fre-
quency of susceptible hosts found that reports of Pv prevalence were consistent with trans-
mission being potentially limited to Duffy positive populations. Finally, reports of apparent
Duffy-independent transmission are discussed. While Pv is evidently not a major malaria par-
asite across most of sub-Saharan Africa, the evidence presented here highlights its wide-
spread low-level endemicity. An increased awareness of Pv as a potential malaria parasite,
coupled with policy shifts towards species-specific diagnostics and reporting, will allow a
robust assessment of the public health significance of Pv, as well as the other neglected non-
Pf parasites, which are currently invisible to most public health authorities in Africa, but which
can cause severe clinical illness and require specific control interventions.
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Author Summary
Plasmodium vivax (Pv) is the most widely distributed malaria parasite globally, but con-
spicuously “absent” from Africa. The majority of African populations do not express the
Duffy blood group antigen, which is the only known receptor for Pv infection. Since this
discovery in the 1970s, the low clinical incidence of Pv in Africa has resulted in a percep-
tion of Pv being completely absent and any apparent cases being misdiagnoses, and no
public health allowances are made for this parasite in terms of diagnosis, treatment or sur-
veillance reporting. As more sensitive diagnostics become available, Pv infection in Africa
is increasingly reported from a variety of different survey types: entomological, serological,
community prevalence surveys, as well as clinical infection data from local residents and
travellers returning to malaria-free countries. A literature review was conducted to assem-
ble these reports and assess the current status of evidence about Pv transmission in Africa.
Moderate to conclusive evidence of transmission was available from 18 of the 47 malaria-
endemic countries examined, distributed across all parts of the continent. Mechanisms
explaining this reported transmission are evaluated, as well as alternative explanations for
the observations. Combinations of complementary explanations are likely, varying accord-
ing to regional ecology and population characteristics. The public health implications of
these observations and recommendations for increased awareness of Pv transmission on
this continent are discussed.
Introduction
Malaria in sub-Saharan Africa has historically been almost exclusively attributed to Plasmo-
dium falciparum (Pf). The identification of the Duffy antigen as the obligate trans-membrane
receptor for P. vivax (Pv) infection of red blood cells by Miller et al. during the 1970s [1,2]
stalled research into the epidemiology of Pv in Africa as indigenous populations on this conti-
nent were known to rarely express the Duffy antigen (and therefore be resistant to infection)
and the dogma of “Pv absence from Africa” became entrenched [3,4]. However, against a back-
drop of increasing appreciation for the clinical severity of Pv infection [5–7], multiple sources
of evidence suggest that Pvmay be more prevalent on this continent than commonly perceived
[3,8–10]. The absence of any thorough effort to unify these sporadic reports, however, pre-
cludes appraisal of their significance, and assessment of the public health significance of Pv in
sub-Saharan Africa.
Plasmodium vivax has certain biological and epidemiological characteristics distinguishing
it from Pf. Lower peripheral parasitaemia of blood-stage infections and a perception of lower
risk of clinical complications during the era of malariotherapy of neuro-syphilis patients [5,11]
contributed to the classification of Pv as “benign”, despite the parasite causing the same spec-
trum of clinical symptoms as Pf [5,7,12,13]. A key difference is the Pv parasite’s ability to form
dormant liver-stages (“hypnozoites”) which evade the human immune system and blood-stage
therapy, and can trigger relapses of clinical episodes weeks to months following the initial
infective mosquito bite [14,15]. Without adequate treatment, hypnozoites therefore impose on
the host a cumulative burden of blood-stage infection, contributing to the disease’s severe
malaria phenotype, notably as severe anaemia [16]. These (and other) life-stage features unique
to Pvmean that several aspects of the control interventions designed against Pf, including pre-
ventive measures related to vector biting behaviour [17,18], diagnosis and treatment [15,19,20]
are not effective against Pv, therefore making this parasite a greater challenge than Pf in achiev-
ing malaria elimination [21,22]. Current WHO diagnosis and treatment guidelines for the
Plasmodium vivax Transmission in Africa
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004222 November 20, 2015 2 / 27
Development Fellow (K00669X) jointly funded by the
UK Medical Research Council (MRC; www.mrc.ac.
uk) and the UK Department for International
Development (DFID; www.gov.uk/government/
organisations/department-for-international-
development) under the MRC/DFID Concordat
agreement and receives support from the Bill and
Melinda Gates Foundation (OPP1068048,
OPP1106023), which also supports BM. DLS is
funded by a grant from the Bill & Melinda Gates
Foundation (OPP1110495), which also supports
RCR. RCR, AJT, DLS and SIH also acknowledge
funding support from the RAPIDD program of the
Science & Technology Directorate, Department of
Homeland Security, and the Fogarty International
Center, National Institutes of Health, USA (www.fic.
nih.gov). The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
WHOAfrican Region (AFR) do not allow for the peculiarities of Pv infections, and are exclu-
sively focused on Pf (see Box 1). Untreated, however, chronic relapses of Pv can cause severe
morbidity and mortality [16].
Box 1. Current WHOGuidelines towards Pv in WHO African Region
(AFR)
Information is taken from the World Malaria Report (WHO, 2014 [29]); Guidelines for
the Treatment of Malaria (WHO, 2015 [30]); Universal Access to Malaria Diagnostic
Testing: An Operational Manual (WHO, 2011 updated in 2013 [84]); and Good Practices
for Selecting and Procuring Rapid Diagnostic tests for Malaria (WHO, 2011 [85]).
Diagnosis
Since 2010, WHO policy is that all suspected malaria cases must be promptly diagnosed
by microscopy or rapid diagnostic test (RDT). An estimated 62% of suspected cases were
tested across AFR in 2013. However, ensuring high quality microscopy is not feasible at
all health-care levels. Instead, RDT use is being scaled-up, and their circulation has dou-
bled since 2010 and accounted for 52% of all diagnoses in 2013.
AFR countries (except for Eritrea and Ethiopia) are recommended to use RDTs that
detect only Pf. These tests have generally higher thermal stability and the Pf-specific anti-
gen HRP2 has highest sensitivity. In the Horn of Africa, combination RDTs using both
HRP2 for detecting Pf and antigens for detecting non-Pf infections are recommended.
Varied antigens are used to detect Pv: either exclusively (pLDH-Pv) or as a non-Pf infec-
tion (pLDH-Pvom) or as an unspecific Plasmodium infection (pLDH-pan). An infection
can only be confirmed as Pv if the RDT includes the pLDH-Pv antigen. Only 5 countries
report using RDTs that include Pv-specific diagnostic capacity (pLDH-Pv): Angola, Eri-
trea, Madagascar, Tanzania, Sudan. Seven countries report the Pf + other (pLDH-Pvom)
RDT combination: Comoros, DRC, Gabon, Namibia, Nigeria, Rwanda, South Sudan.
Eleven use Pf-only RDTs (HRP2), and the remainder of countries (23) did not report
their RDT policy to the WMR in 2014.
Furthermore, RDT product testing demonstrates that only 42% of Pv-specific RDT
tests have acceptable detection scores for low parasitaemia infections, contrasting with
76% of kits for Pf.
Treatment
Radical cure for Pv requires a blood-stage drug and a hypnozoitocide. Chloroquine is the
default, but in areas of resistance, ACTs should be used. Primaquine prevents hypno-
zoite-triggered relapse, but should ideally only be administered to known G6PD normal
patients. In areas where G6PD testing is not available, “a decision to prescribe prima-
quine must be based on an assessment of the risks and benefits of adding primaquine”.
Treatment without primaquine results in repeated clinical episodes and increased risk of
severe morbidity, but primaquine triggers varying degrees of haemolysis in G6PD defi-
cient individuals. Plasmodium vivax-specific treatment policies exist for 7 of the 45 AFR
countries considered here: either chloroquine or artemisinin-based treatment combined
with primaquine in most cases. For the remaining 38 countries, there is no recom-
mended policy tailored to Pv treatment.
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Community surveys in Liberia published in 1949 reported 2.0% of all malaria infections
being due to Pv [23]. However, the acceptance of P. ovale (Po) as a separate species [24,25],
first as a single species and later two [26], and the demonstration of the dependency of Pv on
the Duffy antigen meant that the idea of Pv absence from Africa became entrenched, and dur-
ing the latter part of the twentieth century apparent diagnoses of Pv were routinely reclassified
as Po [3], a morphologically very similar parasite [24]. During this period of near-total reliance
on microscopy diagnosis, Pv largely disappeared from sub-Saharan African epidemiological
records. The rise of the molecular diagnostics era, however, provided the capacity to confi-
dently differentiate human Plasmodium infections [27], and with it came the first substantive
evidence bringing into doubt both the universality of Miller’s observations and the absence of
Pv from populations across sub-Saharan Africa. The other endemic Plasmodium species, Po
and P.malariae (Pm) have lower parasitaemia than Pv [28], so are also historically neglected
by microscopy-based diagnostics, and therefore also rarely recorded without molecular
diagnosis.
While Pv is evidently not a major co-endemic parasite in sub-Saharan Africa, Mendis et al
in 2001 nevertheless estimated an annual burden of 6–15 million cases across Africa [9].
Reports of Pv transmission from almost all countries across the continent [8] further justify
closer investigation. A shifting attitude is discernible in the language of the 2014 World Malaria
Report, which suggests that Pv can occur throughout Africa, but with a low risk of infection
due to high prevalence of Duffy negativity [29]; and the 2015 WHO Treatment Guidelines [30]
indicate that cases are rare outside the Horn of Africa (with the exception of Mauritania and
Mali) [30]. Current WHO guidelines for diagnosis and treatment in AFR, however, do not
reflect this risk, and for example, recommend rapid diagnostic tests that do not detect non-Pf
species. Moreover, most sub-Saharan African countries have no country-specific guidelines for
Pv treatment (see Box 1).
The epidemiology of Pv in Africa remains poorly understood, despite being key to evaluat-
ing the need for adapting current control interventions, to estimating the burden of Pv disease
globally, and to anticipating any changes that may result from reductions in Pf transmission
[22]. Here we assess the existing evidence base of Pv transmission in sub-Saharan Africa and
evaluate the hypothesised mechanisms which may be sustaining this.
Methods
The broad aims of this study were to evaluate what, if any, evidence existed of Pv transmission
in Africa, and to explore whether the small subset of known susceptible individuals (i.e. Duffy
positives) could be sustaining the observed prevalence levels reported from community sur-
veys. Here, details are given about (i) the evidence base assembly, (ii) the unified framework
weighting the evidence, (iii) quantification of the Duffy positive population at risk of infection
(PvPAR), (iv) the prevalence data analysis in relation to PvPAR, and (v) reports of Pv infections
in Duffy negative hosts.
Assembling an evidence base of P. vivax transmission in sub-Saharan
Africa
A PubMed literature search starting 01/01/1985 was run using keywords “vivax” AND “[Afri-
can country names] or [Africa]” (last updated 19/12/2014). Following abstract review for rele-
vance, several categories of data emerged: locally-diagnosed clinical case reports, serological
surveys, observations of infected vectors, cross-sectional prevalence surveys, and reports of
imported malaria into non-endemic countries by infected travellers (Fig 1). The location,
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diagnostic details and numbers of Pv infections were recorded by data type. Pv-specific annual
parasite incidence (API) data reported by health management information systems was also
assembled (see Gething et al 2012 for details [31]).
A further literature search for references about African Anopheles vectors was run (15/12/
2014), using keywords “vivax” AND “[vector species names]”, with the seven dominant vector
species across the Africa region [32]: Anopheles arabiensis, An. funestus, An. gambiae, An.
melas, An.merus, An.moucheti and An. nili; An. pharoensis was also included as a WHO-
defined “major Anopheles species” in certain African countries [29]. The numbers of Pv sporo-
zoite-positive mosquitoes found in each survey location were recorded.
The most commonly used epidemiological metric of malaria endemicity is the parasite rate
(PR), assessed by cross-sectional surveys of infection prevalence [33]. The Malaria Atlas Project
(www.map.ox.ac.uk) PR surveys database, the product of nearly ten years of archiving [33],
was reviewed for evidence of Pv infections reported since 1985 (last updated 17/2/15).
A dataset of imported malaria infections into malaria-free countries by travellers returning
from sub-Saharan African countries was assembled from national and regional (notably the
European Centre for Disease Prevention and Control, ECDC) surveillance programme reports
(search window November 2014 –January 2015). A selection of malaria-free countries with
robust surveillance systems were contacted to obtain summary surveillance data since 2000 on
imported malaria cases into their country. Given that individuals from these non-endemic
countries would have similar prior exposure (i.e. be predominantly immunologically naïve),
their country of origin was not relevant to the analysis, although varied countries were
approached to increase the coverage of countries of infection (for instance, countries from sev-
eral continents [Europe, Americas, Asia, Oceania] and linguistic groups [Dutch, English,
French, German, Portuguese, Spanish, etc]). Contributing countries and the reporting time
intervals which could be assembled are listed in Fig 1. Total numbers of infections were aggre-
gated by probable country of infection.
A weighted framework of the strength of reported evidence of
transmission
A framework was developed to assess the overall evidence of Pv transmission at the first sub-
national administrative level (Admin1). First, the data available for each data type from each
Admin1 were classified as being of category 1 (strongest), 2, or 3 (weakest) evidence (Fig 2),
and second, the scores of the seven surfaces representing each evidence type were summed to
provide an overall assessment of the relative strength of evidence of Pv transmission occurring
in each Admin1. The varied nature of the available data restricted this to being a qualitative
analysis, without aiming at any quantitative estimate of endemicity/incidence or quantitative
comparison with other Plasmodium parasites. The absolute number of positive reports was
used as the metric of strength of evidence, rather than any proportional metric.
The criteria for each evidence category varied according to the time window of exposure
represented by the data type (and thus the probability of local infection), the denominator size,
and the diagnostic method sensitivity/specificity. For example, due to their limited range of
movement, infected vector specimens were considered relatively strong evidence of local trans-
mission. In contrast, the longer window of exposure detected by serological surveys meant
sero-positivity could result from a transmission event in a different location prior to relocation
to the study site. To reflect the reduced temporal specificity of the serological evidence, a rela-
tively higher number of reports of sero-positive individuals was therefore necessary to provide
the same strength of evidence of transmission as infections observed in real-time. The single
time-point snapshot investigated during a community prevalence survey contrasts with a
Plasmodium vivax Transmission in Africa
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Fig 1. Data assembly procedure. The geographic extent of the analysis included the 47 malaria-endemic countries of sub-Saharan Africa: all WHO African
Regional Office countries except Algeria (0 indigenous cases in 2013 [29]), but including Djibouti, the Republic of Sudan and Somalia. ECDC: European
Centre for Disease Prevention and Control. *Prevalence survey analyses were limited to those with sample size50.
doi:10.1371/journal.pntd.0004222.g001
Fig 2. Weighting of the different data types at Admin1 level.Ranks refer to the relative strength of the evidence as an indicator of ongoing Pv
transmission in an area. *The total number of returning traveller infections from each country was divided between the number of Admin1 regions per
country. If there was less than 1 reported infection per Admin1, the weighting score was 0.5. Note that because the traveller infections data were
retrospective and not sub-nationally specific, it was not possible to distinguish the Republic of Sudan from South Sudan, thus results were considered for
Sudan pre-separation and the same score allocated to both countries based on the overall data.
doi:10.1371/journal.pntd.0004222.g002
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much larger time window and population denominator for clinical case reporting across a
region. Therefore, evidence of parasitaemia from prevalence surveys was considered stronger
evidence of ongoing transmission than routine reporting of symptomatic cases, and a larger
number of positive symptomatic individuals was required to equate to the strength of evidence
of asymptomatic infections from prevalence surveys. Annual Parasite Incidence data (API)
indicating stable transmission (1 case/10,000) equated to the strongest category 1, while
unstable transmission (<1 case/10,000) was category 3.
Clinical cases diagnosed by molecular diagnostic tools based on nucleic acid amplification
techniques (notably PCR) were considered stronger evidence of transmission than by light
microscopy or rapid diagnostic tests (RDT) due to the increased species-specific diagnostic
accuracy. In the case of prevalence surveys, however, where infections were more likely to be of
low parasitaemia, RDT and microscopy were expected to diagnose a smaller proportion of
total infections than PCR-based diagnostics due to their differing limits of the detection [28]. It
has been estimated that molecular diagnostics identify at least double the number of infections
compared to conventional methods [34]. Therefore the numbers of infections diagnosed by the
two methods correspond to differing proportions of the true parasite prevalence, with RDT
and microscopy-based underestimating true prevalence. On the other hand, RDT and micros-
copy diagnostics were less specific. These two aspects therefore balanced out and it was consid-
ered that prevalence data from both diagnostics would correspond to similar strength of
evidence of transmission.
Reports of Pv infection among travellers returning from African countries could not be
attributed the same strength of evidence as observations of infection among local residents.
The relapsing nature of Pv parasites means that infections could have been acquired from travel
prior to the reported journey. Furthermore, the nature of the imported infections dataset
assembled here is highly opportunistic and incomplete. This data type was therefore down-
weighted relative to reports of local infections.
The data were mapped to the Admin1 level. Where multiple surveys within a data type were
available from a single administrative region, the scores were based on the total number of
reports. Returning traveller infections were only reported to the national level, so to allocate
scores to Admin1 units, the overall number of reported Pv infections was divided by the total
number of Admin1 units in the country. These infections were therefore strongly down-
weighted relative to the other data.
Finally, once the component data types were categorised and mapped, these were summed
together in ArcMap 10.1 [35]. The weighting system accounted both for the strength of evi-
dence in each category and for corroboration between data types: the more data types reporting
Pv transmission, the higher the overall strength of evidence. The highest level, “conclusive evi-
dence”, was only attained if two or more category 1 sources of evidence were available. The
lowest level, “very weak evidence” corresponded to Admin1 units from which no direct evi-
dence was available, only a relatively small number of infected traveller reports (less than 1 case
per number of Admin1 units, thus a low probability of local transmission).
Estimating the population at risk of infection
Using an approach similar to that previously published [8,31], the geographic limits of Pv
transmission were overlaid onto a 2015 population surface to estimate the PvPAR. Medical
intelligence data and biological exclusions were applied to define the limits of potential trans-
mission. First, API and routinely reported incidence data were reviewed [31] to identify areas
which could be excluded for being risk-free of malaria; this exclusion was not species-specific
due to the previously discussed imperfect diagnostic capacity of most countries, but instead
Plasmodium vivax Transmission in Africa
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only areas defined as “malaria free” were excluded. Second, areas where temperatures could
not support Pv sporogony at any time in an average year were excluded by a modelled tempera-
ture suitability mask [36]. Aridity was not used as exclusion given that man-made conditions
can facilitate vector breeding even in areas of extreme aridity; previous PvPAR estimates have
“downgraded” risk from stable to unstable transmission levels based on aridity, but the lack of
distinction between these levels here means no aridity exclusion was applied. Third, urban
areas, as identified based on the Global Rural Urban Mapping Project (GRUMP) urban extents
layer [37], were excluded. While potentially overly-conservative, the exclusion of urban popu-
lations was consistent with previous PvPAR estimates [8,31], and is based on the significantly
lower infection risk in urban areas [38,39].
A population surface for 2015 was compiled from theWorldPop Project projections (www.
worldpop.org), supplemented by data from the Gridded Population of the World (GPW) v3
(http://sedac.ciesin.columbia.edu/data/set/gpw-v3-population-count-future-estimates) for the
Comoros and São Tomé and Príncipe, which were not available fromWorldPop. This was
adjusted to the Duffy positive population using the previously published Duffy blood group fre-
quency maps developed by geostatistical modelling of population surveys of blood group fre-
quencies [4]. The median model prediction of the Duffy surface was used, together with the 25%
and 75% quartiles (50% confidence interval) of the Duffy model outputs. National-level PvPAR
estimates were derived for the three Duffy thresholds within the defined limits of transmission.
All spatial manipulations were run at 5 x 5 km resolution in ArcMap and ArcScene 10.1 [35].
Investigation of reported PvPR in relation to the Duffy positive PvPAR
The PR database was used to investigate aspects of Pv transmission across sub-Saharan Africa and
compare them to the PvPAR and to Pf. Estimates of the prevalence of Duffy negativity at the PR
survey locations were extracted from the modelled Duffy group frequency maps [4]. For the com-
parisons with Pf, only surveys with the diagnostic capacity to identify both species were included,
ensuring that paired estimates of PvPR and PfPR were matched in space, time, and population
sample characteristics. The analysis was also restricted to surveys of50 individuals. A trio of spa-
tially-matched estimates were therefore collated for PvPR, PfPR and Duffy negativity prevalence.
This dataset was used to assess: (i) whether the observed PvPR values were consistent with
infections being potentially limited exclusively to Duffy positive hosts, (ii) how the prevalence
of infection and relative risk of infection differed between species among their specific subset of
known susceptible hosts (based on the assumption that the PvPAR was limited to Duffy posi-
tive hosts: PvPRFy+ = PvPR/Proportion of Duffy positive hosts), (iii) the relationship between
infection prevalence of the two species, and whether prevalence of one could inform predic-
tions of the other. Full methodological details are available in Text S1.
Collating reports of P. vivax infections in Duffy negative hosts
Reports of Pv infections in Duffy negative hosts were compiled from the different data types
reviewed. Only studies that used molecular confirmation of both Pv infection and Duffy geno-
type were included. The reports were geopositioned and presented in relation to the local prev-
alence of Duffy blood group phenotypes estimated by the modelled geostatistical maps [4].
Results
Evidence of transmission: The data
The literature search identified 1,479 publications, of which 529 were considered relevant to
studies of Pv in Africa. All reports of Pv infection were collated and geopositioned (Fig 3). A
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total of 15 surveys reporting infected Anopheles vectors were identified (S1 Table), as well as six
reports of Pv sero-positivity (S2 Table), 109 sites with local Pv case reports (S3 Table) and 643
Pv-positive community prevalence surveys (www.map.ox.ac.uk). Overall, reports of Pv were
available from 21 of the 47 malaria-endemic countries examined. The maps in Fig 4 represent
the aggregated scores mapped to the Admin1 level.
Records of Plasmodium infections in travellers were accessed for 31 malaria-free countries,
corresponding to a period of 182 surveillance-years between 2000 and 2014 (Fig 1). Overall,
1,339 Pv infections were reported from 42 suspected countries of infection spread across sub-
Saharan African countries, corresponding to all but five countries considered here. Fewer than
20 cases of Pv were reported from 24 countries, while from nine countries there were 20–50
cases, and nine countries were associated with infection of 50 of more travellers over the
Fig 3. The evidence base of Pv occurrence in sub-Saharan Africa. All points represent a positive diagnosis of Pv. See S1–S3 Tables for original data.
doi:10.1371/journal.pntd.0004222.g003
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reporting period. The number of cases that our searches assembled and the proportion of Pv
infections relative to Pf are shown in Fig 5, though these ratios were not included in the evi-
dence-weighting framework which focussed exclusively on Pv with evidence strength classifica-
tions based on categorical classifications and not a quantitative analysis. Limitations to this
dataset are discussed below.
Evidence of transmission: The composite map
The composite map in Fig 6 reflects the strength of the overall available evidence in each
Admin1 unit (summarised by country in S5 Table). Of the 629 Admin1 units across malaria-
endemic Africa, there were 28 units for which no evidence of transmission was identified
(island nations of Cape Verde and Mayotte, and the small states of Guinea-Bissau and Swazi-
land). In 488 Admin1 units, the only available evidence was from traveller infections, so evi-
dence of transmission from these areas was considered weak (n = 217) or very weak (n = 271).
Of the remaining Admin1 units from which direct evidence was identified (n = 113), eight had
conclusive evidence (in Ethiopia, Madagascar and Mauritania), 20 had strong, 36 moderate
and 49 weak evidence of local transmission. Overall, there was moderate to conclusive evidence
of Pv from 18 countries, including four in West Africa, three in Central Africa, three in East
Africa, two in Southern Africa, and all six countries of the “Horn of Africa+” (HoA+) region
(which included Djibouti, Eritrea, Ethiopia, Somalia, Sudan and South Sudan). The weaker evi-
dence categories represent areas of relatively higher uncertainty.
Fig 4. Summaries of the overall category of evidence available for each data type at the Admin1 level. Evidence categories are defined in Fig 3. Panel
A represents evidence of Pv from infected vectors, Panel B sero-positivity, Panel C Pv community prevalence surveys, Panel D molecularly-diagnosed
clinical cases, Panel E microscopy-diagnosed clinical cases and Panel F annual Pv incidence data. See S1–S3 Tables for original data.
doi:10.1371/journal.pntd.0004222.g004
Plasmodium vivax Transmission in Africa
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Population at risk of infection
An estimated 86.6 million individuals were at risk of Pv infection (PvPAR) across sub-Saharan
Africa in 2015 (interquartile range, IQR: 43.9–156.7 million; S6 Table). These individuals were
Duffy positive hosts living outside urban areas across malaria-endemic Africa where tempera-
tures were suitable for sporogony at some point during an average year. The confidence inter-
val is based only on the IQR of the Duffy positive frequency surface [4], without accounting for
uncertainty in the population density dataset or the temperature suitability surface. The binary
Fig 5. Traveller infections mapped to probable country of infection. The relative contribution of Pf and Pv infections is reflected in each pie chart (with
charts sized by overall number of infections, transformed on a square-root scale). Numbers indicate the number of exported Pv infections identified by this
study (corresponding to the dark blue segment of the pie chart). Infections date from 2000 to 2014; data sources and countries of importation are listed in Fig
1. Where species-specific information was available for mixed infections, these were considered to be separate infections, so a single individual would have
contributed two or more infections to the total count of malaria parasite infections. Returning patients for whom a single country of probable infection could not
be determined were excluded.
doi:10.1371/journal.pntd.0004222.g005
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adjustment excluding risk of urban transmission results in a conservative PvPAR estimate
which is also not represented in the confidence interval.
Overall, 28% of the PvPAR was outside the HoA+ region, with 10.0 million in East Africa
(4.7 million excluding Madagascar), 7.2 million in West Africa, 4.1 million in Southern Africa
and 3.3 million in Central Africa (S6 Table). In 12 countries distributed across all sub-regions,
the national PvPAR was greater than one million; Ethiopia, Sudan and Madagascar carried the
highest PvPARs. The spatial distribution of the PvPAR is illustrated in Fig 7, showing clustered
areas of relatively increased PvPAR across the continent.
Fig 6. Composite map of the evidence of Pv transmission in sub-Saharan Africa, summarised to the Admin1 unit.
doi:10.1371/journal.pntd.0004222.g006
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Investigation of PvPR in relation the Duffy positive PvPAR and to PfPR
Transmission of Pv in sub-Saharan Africa has been considered unlikely given the high preva-
lence of Duffy negativity across the continent. However, the evidence indicates that Pv is pres-
ent, so here we investigated (i) whether the observed infection rates could be consistent with
transmission exclusively limited to Duffy positive hosts, and (ii) how Pv and Pf infection rates
were related to one another in sub-Saharan Africa. Full discussion of the results of these analy-
ses and additional figures are available in the Supplementary Information (S1 Text and S1–S3
Figs).
The data (Fig 8A) were first examined for consistency with transmission within the Duffy
positive population subset. The scatter of the data in Fig 8B being almost exclusively concen-
trated below the x = y dashed line (1,540 of 1,546 surveys) indicates that the proportion of indi-
viduals infected does not exceed the proportion of the population considered susceptible, thus
fulfilling the necessary condition (but without proving) that Duffy negativity imposes an upper
Fig 7. Spatial map of the distribution of the PvPAR. The map resolution is 5 x 5 km, and the 3-dimensional scale was square-root transformed to allow
plotting.
doi:10.1371/journal.pntd.0004222.g007
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threshold on PvPR by infections being limited to Duffy positive hosts. Six PvPR values (1.7% of
positive surveys) were outliers to this, all from coastal areas of Western/Central regions, includ-
ing 4 from São Tomé and Príncipe. The survey with the highest discrepancy was from Camer-
oon, where 13 of 269 individuals were PCR-Pv positive [40]. Fig 8B also indicates PvPR rising
as the frequency of susceptible hosts increases, as would be expected.
Next, PvPR estimates were re-scaled to prevalence of infection among the subset of Duffy
positive hosts (PvPRFy+ = PvPR/Proportion of Duffy positive hosts). S1 Fig plots PvPRFy+
against PfPR, revealing distributions of points across the graphs without any clear trends
emerging between infection rates between species. Regional trends, however, were apparent,
with higher relative risk of infection in regions of lower host availability. For instance, where
PvPRFy+ was positive in the Western region (n = 13), all surveys showed higher likelihood of
infection by Pv than Pf (among the respective susceptible population sub-groups) (S1 and S2
Figs). In areas where Duffy positive hosts were rare (across most of sub-Saharan Africa these
are<5%), these individuals were at a higher risk of being infected by Pv than by Pf (S2 Fig). As
Duffy positive hosts become more common, the relative risk of infection becomes more evenly
distributed around 0.
Finally, a logistic regression model was developed to test for an association at the population
level between the parasite rates of the two species: could PR data from one species predict PR
of the other? No significant relationship could be identified from the paired PR dataset for sur-
veys outside the HoA+, and the association was not significantly different from a flat line (S3
Fig). Within the HoA+, PfPR was a highly significant predictor of PvPRFy+ (p = 4.4x10
-6) up
to 15% PfPR, after which increases in PfPR did not result in further predicted increases in
PvPRFy+; in contrast, PvPRFy+ within the HoA+ was a significant linear predictor of PfPR at all
levels of endemicity. Substantial scatter and heterogeneity in the data, however, resulted in
Fig 8. Characteristics of the PvPR dataset (n = 1,546).Only surveys of50 individuals are included, and PvPR values are adjusted to the 1–99 age range.
Panel A shows the PvPR values, their spatial distribution and the diagnostic method used for each survey. Panel B is a scatterplot of the relationship between
the proportion of the population at risk of Pv infection (represented by the proportion of the population Fy+) and the proportion of individuals infected with Pv
(PvPR).
doi:10.1371/journal.pntd.0004222.g008
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wide 95% confidence intervals around the predicted relationship even when a significant rela-
tionship was identified.
Reports of P. vivax infection in Duffy negative hosts
The last few years have seen evidence emerging of Pv infections in Duffy negative hosts (Fy-Pv
+ infections), providing an additional potential mechanism sustaining Pv transmission across
sub-Saharan Africa. These observations are from diverse geographic, demographic and host
genetic landscapes. The PubMed literature review identified 19 sites across 6 countries of sub-
Saharan Africa where Fy-Pv+ infections in 54 individuals have been confirmed by molecular
diagnosis, all published 2010–2015 (S4 Table and Fig 9). Observations of Fy-Pv+ infections
were widely distributed across the continent, including in populations with heterogeneous
Duffy phenotypes (with correspondingly higher PvPAR: Ethiopia and Madagascar) as well as
in populations where Duffy negativity was at near fixation (where PvPAR was much lower:
Angola, Cameroon, Equatorial Guinea and Mauritania). All Fy-Pv+ infections (except one sur-
vey from Yaoundé, Cameroon) were from areas classified as “rural” by GRUMP. The observa-
tions were from areas of varied population densities, ranging from<100 to>500,000
individuals in the surrounding 25 km2 area (WorldPop Project data). Both symptomatic and
asymptomatic Fy-Pv+ infections were reported. The reported repartition of Pv infections
among Duffy negative and positive hosts ranged widely between surveys (S4 Table), but the
data did not permit any formal analysis of differential infection risk.
Discussion
It is evident that Pv is not absent from Africa. There is robust evidence from a variety of corrob-
orating sources of Pv transmission across all sub-regions, with direct evidence from 21 of the
47 countries considered, and 42 countries are attributed with infection of visiting travellers.
Overall, there was moderate to conclusive evidence of Pv transmission from within 18 coun-
tries. The remaining countries either had only weak evidence of transmission or no evidence
could be found at all. These observations of widespread Pv infection should not be surprising: a
suitable environment, competent vectors and susceptible human hosts make it unlikely that
the parasite would not be present. The implications of the present Pv-specific study apply to all
non-Pf species: without adequate diagnosis and reporting, their true public health burden can-
not be determined. While Po and Pm are more widely acknowledged to be endemic to parts of
Africa, Pf-specific diagnostics will not diagnose the low-level parasitaemia and non-specific
symptoms that the non-Pfmalarias present as, and radical cure is not available for either of the
relapsing species, Pv or Po.
The opportunistic and highly varied nature of the available surveys restricted the sophistica-
tion of potential analyses, limiting the composite map to being a qualitative assessment of avail-
able evidence rather than providing any quantitative measures or comparisons with other
parasite species. For instance, varied molecular diagnostic methodologies or inconsistent
approaches for calculating sero-prevalence meant that standardization was not possible even
within each data type, therefore favouring the categorical approach. The limited distribution of
the data means that the resulting evidence map is both a map of sampling effort and of Pv pres-
ence in those sampled areas. Greater survey coverage would allow a distancing from the depen-
dency on sampling effort. The traveller data are also biased according to popular travel
destinations, and suffer further limitations: (i) the data assembled here are incomplete, formed
from an opportunistic selection of countries and reporting years. The numbers of infections
cannot be interpreted in any absolute sense; (ii) data are reported only to the national level,
whereas the analysis was sub-national; (iii) suspected countries of infection may not be fully
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reliable given Pv’s ability to form latent infections. In recognition of these limitations, traveller
data were therefore strongly down-weighted relative to other data types but nevertheless repre-
sented an important and complimentary component of the evidence of Pv transmission.
Although there were additional surveys reporting “zero Pv”, these were not incorporated
into the evidence synthesis as they could not be interpreted as “absolute absences” [43], partic-
ularly given the lower sensitivity of conventional microscopy and RDT methods to Pv than Pf
Fig 9. Published observations of molecularly-confirmed Pv infections in Duffy negative individuals across Africa (Fy-Pv+). Yellow stars represent
the number of Fy-Pv+ infections identified at each study location (including some as mixed infections with other Plasmodium species). Original citations and
further details are given in S4 Table. Pie-charts summarise the predicted prevalence of the Duffy phenotypes in each country [41]. The background map is
the predicted frequency of Duffy negativity [4]. Further Fy-Pv+ infections from western Kenya have been reported [42], but the diagnoses were inconclusive,
so are not included in this map.
doi:10.1371/journal.pntd.0004222.g009
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[27,29] which often underestimate the true prevalence of blood-stage Pv [44–48], especially in
mixed infections [49]. The low anticipated prevalence of Pvmeans that very large sample sizes
and diagnostic tools with higher sensitivity for detecting Pv would be needed to reliably give
any confidence of “absence”.
While Pv infection levels appear plausible with transmission being restricted to the Duffy
positive population at risk (estimated at 86.6 million), a number of other explanations dis-
cussed here have also been hypothesised to explain the observed infections.
Transmission among Duffy positive hosts
The PR data were found to be consistent with transmission being potentially sustained by
Duffy positive hosts alone. However, an important limitation to the PR comparative analysis
was the skewed distribution of positive surveys, with the majority coming from the HoA+
(73%), while the main area of interest was outside this region. The lack of any predictable asso-
ciation between PvPRFy+ and PfPR in regions outside the HoA+ suggests that change in the
prevalence of one species is not reflected by the prevalence of the other species at the host pop-
ulation level. This outcome may indicate that the two infection rates are determined by differ-
ent drivers of transmission linked to their differing biological characteristics, notably capacity
to relapse. For instance in these areas of low Duffy positive host availability, the environmental
drivers that are highly significant determinants of PfPR endemicity [50], may be secondary to
the impact of the local host dynamics for predicting PvPRFy+. Alternatively, the noise from the
heterogeneity of the small dataset (exacerbated by the PvPR adjustment to PvPRFy+) may be
masking a relationship similar to that in the more data-rich HoA+ region which would be pos-
sible to detect through a larger dataset.
Bespoke transmission models accounting for relapse risks and the peculiarities of the pre-
dominantly Duffy negative landscape are required in order to estimate the critical community
sizes and determine the transmission dynamics needed to sustain infection, to verify the plausi-
bility of Pv in Africa being limited to Duffy positive individuals [51–56].
The quantitative PR data analysis presented here is heavily contingent on the Duffy negativ-
ity frequency map [4]. Of the 203 population surveys which informed that map, 41% were pub-
lished pre-1990. The increase in large-scale population movement since this time [57,58]
means that an influx of Duffy positive alleles to the gene pool may be increasing the frequency
of susceptible hosts with a strongly spatially clustered distribution, making the 86.6 million
PvPAR estimate a potentially significant underestimate. Furthermore, the historical waves of
migration from Duffy positive British, French, Indian, Lebanese, Portuguese etc, populations
may also be underrepresented. The wide confidence interval of the PvPAR (43.9–156.7 million)
indicates the potential impact of changes to the Duffy maps. Furthermore, the GRUMPmap
which was used to identify urban populations for exclusion from the PvPAR, overestimate
urban areas, so many high density rural populations may have been excluded, further contrib-
uting to a conservative PvPAR estimate.
Plasmodium ovalemisdiagnoses
Plasmodium ovale represents an important potential confounder to the reliability of micro-
scopic reports of Pv due to their morphological similarities [24] and the risk of Pv reports actu-
ally being misdiagnosed Po infections. Conversely, the opposite may also be true with Pv
infections being misclassified as Po due to the belief of Pv absence [3]. Microscopy-based diag-
noses were down-weighted relative to PCR-based data in the evidence framework to account
for these uncertainties. There is also potential for cross-reactivity between Po- and Pv-specific
antigens in serological screening. Little is known about the diversity of Po in particular, so
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there is a need for the development of additional species-specific reagents to reliably distin-
guish the two species.
The finding of Pv being a common cause of traveller infections is consistently reported from
varied sources (Fig 5). For instance, of 618 cases of Pv imported into Europe between 1999 and
2003, 33.8% were reported to have been infected in Africa [59]. While molecular confirmation
is not routine for returning traveller infections, this is increasingly common in China where
thorough case investigations differentiate imported from indigenous cases [60]. Recent investi-
gation of malaria infections among gold miners returning to China from Ghana after a median
travel time of one year, found 42 of 874 infections were Pv and 1 was Po [61]. From a public
health perspective, even if these several hundreds of infections are all misdiagnoses, given that
the same treatment guidelines for radical cure apply to both species [30], the potential misdiag-
nosis is not significant in terms of treatment policy and requires the same increased diagnostic
capacity away from the perception of Pf exclusivity.
Relapse as a confounder
A potential confounder to attributing all the assembled evidence of Pv to local transmission in
Africa is the parasite’s ability to form dormant hypnozoites and present clinical symptoms only
after a delayed period during which the patient may have travelled widely [14,62]. The evi-
dence-weighting framework attempted to account for this possibility through the differing
thresholds between categories. Again, though, even if a subset of the observed cases resulted
from infection events elsewhere, the implications for diagnostic and treatment policy remain
the same: appropriate capacity is required in the area of clinical presentation, irrespective of
where transmission occurred.
Zoonotic transfer from an ape reservoir
Liu et al [63] have published conclusive evidence of the origin of human Pv being from a genet-
ically diverse parasite population whose natural hosts are gorillas and chimpanzees in Africa.
Although the human parasite clade is distinct from the more diverse parasite strains that indis-
criminately infect various ape species, there is evidence (from one individual) of the plausibility
of cross-infection of parasite strains between ape and human hosts with similar clinical presen-
tation [63,64]. Liu et al therefore argue that Pv infections reported from regions of high Duffy
negativity frequency are zoonotic infections spilling over from ape reservoirs. Entomological
evidence suggests that An.moucheti and An. vinckeimay be potential vector species bridging
transmission between apes and humans [64,65], although the entomological evidence is very
limited with only one reported infected specimen of each species and vector behaviour that is
not conducive to frequent transmission events.
The natural ranges of these ape reservoir species are restricted to the forests of Central
Africa (Fig 10). So, while this infection mechanism may explain transmission in specific con-
texts, this does not represent a universal explanation for the evidence of Pv across predomi-
nantly Duffy negative regions of Africa.
Duffy-independent transmission
The reports of Duffy negative infections from diverse epidemiological settings (54 molecularly-
confirmed symptomatic and asymptomatic infections identified across 19 sites; S4 Table) rep-
resent a further potential mechanism sustaining Pv transmission across Africa. The public
health burden of these infections is unclear. While the protective effect of Duffy negativity may
not be as absolute as previously considered, this blood group’s high frequencies across Africa
do nevertheless appear to represent a limiting force on potential Pv endemicity. In the absence
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of any limiting factor, and given the presence of competent vectors and a suitable climate, rates
of Pv infection comparable to those in Asia or the Americas [31] would be expected. Fy-Pv+
infections demand further investigation, ideally across diverse epidemiological settings. The
impact of reduced protection conferred by Duffy negativity (currently assumed to be 100%)
would have important impacts on the resulting PvPAR (see estimates in Zimmerman et al
[67]).
Fig 10. Observations of Pv across Africa in relation to the distributions of hypothesised ape reservoir hosts [63] (based on the IUCN Red List of
Threatened Species distribution maps [66]) and regions of highest frequencies of Duffy negativity (Fy(a-b-)) [4].
doi:10.1371/journal.pntd.0004222.g010
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Complementary transmission mechanisms across a highly diverse
continent
For the first time, this paper synthesises all available evidence of Pv transmission in Africa, and
evaluates the varied mechanisms hypothesised to explain these observations across an area
where transmission is largely unexpected. Here we argue that no single theory is sufficient to
explain transmission across this varied continent, but instead, transmission pathways vary
according to the complex ecology and epidemiology of each area and population.
Evidence relating to Pv transmission across Africa appears inconsistent. Pv is clearly widely
present, causing a substantial proportion of returning traveller malaria infections, clinical ill-
ness and asymptomatic infection among local residents, infecting vectors and presenting a his-
tory of exposure by local communities to infected bites. However, extensive surveys using
high-sensitivity molecular methods have repeatedly failed to diagnose Pv [68–70]. For instance,
PCR-based screening of 1,402 blood samples in southern Cameroon found no trace of Pv [69],
while a nearby PCR-based community survey of 269 individuals diagnosed a prevalence rate of
5% PvPR (representing 13.8% of all Plasmodium infections) [40]. The key difference between
these neighbouring surveys in southern Cameroon was the demographic composition of the
sampled populations: while no Pv was found in the remote, rural village communities [69], the
multi-ethnic and highly cosmopolitan population did have Pv [40].
While there is some evidence of an ape reservoir enabling zoonotic infections, this does not
preclude the possibility of endemic transmission. Fig 10 makes evident the observations of Pv
outside these ape natural ranges, and furthermore, the main group of travellers returning from
Africa with Pv infections are visiting relatives [71,72], and less likely to visit the tourist attrac-
tions which would bring them into contact with infected vectors [73]. Therefore, while there is
evidence of the zoonotic reservoir being a contributing source of infection, other mechanisms
of transmission (and reservoirs of infection) must also be involved.
The multiple theories discussed so far for explaining the observations of Pv in Africa are not
mutually exclusive. Instead, given the limitations to each hypothesis for explaining the overall
diversity of transmission, it seems probable that all are involved to some degree. The dominant
source of infection would vary between location: in remote forest areas, infections may be from
the ape reservoir [64], while in more cosmopolitan areas, transmission may be being sustained
by an admixed Duffy positive population. The early production of gametocytes in infections
[20] means that even where the host has developed immunity to symptomatic blood-stage
parasitaemia from prior exposure, short-lived sub-clinical infections could still be helping to
sustain transmission. It is likely that some reported cases of Pv are in fact Pomisdiagnoses, but
the sheer abundance of data from various diagnostic methods means this cannot be universal.
Similarly, while there is convincing evidence of Fy-Pv+ infections, these are not reflected by the
widespread Pv endemicity levels that would be expected if these infections were commonplace.
The epidemiology of Pv in Africa is likely to be complex and multi-faceted, driven by different
mechanisms in different regions, determined by the unique host genetic, vector, and reservoir
characteristics of each area. These complimentary theories together may explain the observed
evidence of Pv transmission. High sensitivity molecular methods could allow further insight
into the population genetics of Pv infections diagnosed in Africa and therefore their epidemiol-
ogy [74], as well as helping to define true exposure and risk of exposure to infection.
Public health implications of widespread P. vivax infection risk
The non-specific clinical presentation of malaria means that diagnosis is only possible with a
parasitological test [30]. The WHO T3 policy to “Test, Treat, Track” all cases of malaria is very
logical in an era of resistance emergence and falling endemicity in many areas [75]. However, it
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becomes harmful if the “Test” component is not capable of detecting all potential parasites. In
the many African countries exclusively reliant on HRP2-based RDT diagnosis (see Box 1), Pv,
Po and Pm infected patients who present in clinics with fever symptoms will test negative and
could leave untreated. The patients will persist in the community as sources of onward trans-
mission, and, in the case of Pv and Po, be susceptible to the cumulative impact of clinical
relapses.
In turn, therapeutic options for Pv are inadequate. While Pf-targeted control will treat Pv
clinical symptoms, it will not impact on the parasite reservoir sustaining the observed blood-
stage clinical infections. Even in terms of blood-stage therapy, drug policy in Ethiopia (ranked
fourth largest contributor to Pv cases globally [29]) maintains chloroquine as first-line treat-
ment despite reports of resistance [76]. A further complication to delivering Pv-specific therapy
in Africa is the high prevalence of glucose-6-phosphate dehydrogenase deficiency (G6PDd)
[77], causing a potentially dangerous intolerance to primaquine, the only available drug for
treating the liver-stage parasites [78]. The same issues apply to Po radical cure. It has been
hypothesised that the high prevalence of G6PDd may be the result of a selective advantage
against malaria [79–81], meaning that G6PDd might be under-represented in Pv patients and
thus primaquine therapy a lesser concern. However, given Pv’s preference for invading reticu-
locytes–young red cells with highest levels of G6PD enzyme activity–it is unlikely that a rela-
tively mild G6PD variant (such as G6PDA-, the predominant African variant [82]), would
provide any protective advantage against Pv infection.
Finally, the evidence presented here has two main implications for Pvmapping. First, where
PvPR surveys are available, the infection rates reported are consistent with transmission only
among Duffy positive hosts. This therefore supports the approach previously followed of
restricting the PvPAR to Duffy positive hosts [8,83] and of using the frequency of Duffy posi-
tive hosts as an upper threshold to the maximum potential prevalence of infection [31]. Second,
the PfPR surface cannot be used to predict Pv infection prevalence in Duffy positive hosts,
except potentially in transmission settings up to 15% PfPR in the HoA+ region.
Conclusions
The implications of this paper should not be misinterpreted. This is not a “call to arms” requir-
ing huge additional resources above and beyond the considerable efforts already ongoing into
control of Pf. Current epidemiological data overwhelmingly indicates that Pf is the predomi-
nant malaria pathogen across most of sub-Saharan Africa [29,31,68], and that where present,
Pv prevalence remains low. Nevertheless, despite the estimated 86.6 million individuals at risk
of infection, Pv is so drastically neglected across this vast and populous continent that without
a commitment to add capacity for Pv in routine surveillance and reporting, this minor player
will remain invisible and any quantitative burden estimates and evidence-based policy deci-
sions impossible. Broadening the outlook beyond Pf would simultaneously also strengthen the
evidence base relating to the other neglected endemic species, Po and Pm and increase access to
diagnosis and treatment of these other neglected malaria species.
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S1 Text. Supporting methods and results: Investigation of the PvPR data in relation to host
population characteristics and PfPR.
(DOCX)
S1 Fig. Prevalence of infection by Pf (PfPR) in relation to PvPR among Duffy positive hosts
(PvPRFy+). Panels A and B show the full dataset (n = 1,546); Panels C and D have surveys
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reporting zero prevalence of either species excluded (n = 249). Panels A and C represent preva-
lence 0–1; while B and D provide higher resolution of 0–20% prevalence. The six surveys where
PvPR exceeded the proportion of Duffy positive hosts were excluded as anomalies.
(TIF)
S2 Fig. Regional summaries and relative differences in PvPRFy+ and PfPR (log trans-
formed). Panel A boxplot summarises differences within regions, while Panel B shows relative
risk of infection between species in relation to the proportion of Duffy positive hosts, and
Panel C shows the relative infection risk in relation to the density of Duffy positive hosts
(n = 249).
(TIF)
S3 Fig. Logistic-regression model predictions using PR values of one species to predict
those of the other (n = 249). The dependent variable is plotted on the y-axis. The PvPR values
are adjusted to infection rates in the subset of Duffy positive hosts (PvPRFy+). The solid line
represents a significant model fit, while a dashed line indicates that there is no relationship sig-
nificantly different from zero.
(TIF)
S1 Table. Reports of wild-caught Pv-infected mosquito vectors. (NR: not reported.)
(XLSX)
S2 Table. Reports of serological studies with positive reports of Pv. (NR: not reported.)
(XLSX)
S3 Table. Local case reports of Pv infection among patients in Africa. (NR: not reported.)
(XLSX)
S4 Table. Reports of Duffy negative hosts infected by Pv. (NR: not reported.)
(XLSX)
S5 Table. Summary Admin1 classifications by country. (NR: not reported.)
(XLSX)
S6 Table. National PvPAR estimates. (NR: not reported.)
(XLSX)
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